-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In ChAdOx1 nCoV-19 encoding SARS-CoV-2.
Immune Thrombosis Here, this article reports three VITT patients with ischemic stroke.
Patient 1, a 35-year-old Asian female, had onset of right temporal and periorbital headache a few days after receiving ChAdOx1-nCoV-19 vaccine.
Blood vessel
Patient's cerebrovascular impact
Patient's cerebrovascular impactPerson 2 was a 37-year-old white female who developed diffuse headache, loss of left visual field, confusion, and left arm weakness 12 days after the ChAdOx1 nCoV-19 vaccine.
Patient 3, a 43-year-old Asian male, developed a language barrier 21 days after the ChAdOx1 nCoV-19 vaccine.
Observations have shown that in addition to venous thrombosis, the clinical symptoms of VITT include arterial occlusion.
Management includes intravenous immunoglobulin, methylprednisolone, plasma exchange, and non-heparin anticoagulants such as fondaparinux, argatroban, or direct oral anticoagulants.
Endovascular treatment or decompressive craniectomy can also be used for carefully selected patients Al-MayhaniT ,SaberS ,StubbsMJ Al-MayhaniT Al-Mayhani SaberS Saber StubbsMJ Stubbs , et al bmj.
com/content/early/2021/05/20/jnnp-2021-326984" target="_blank" rel="noopener">Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopaenia Journal of Neurology, Neurosurgery & Psychiatry Published Online First: 25 May 2021.
Published Online First: doi: 10.
1136/jnnp-2021-326984 doi:
leave a message here